PLA2G7 and coronary artery disorder: For example, for the Val279Phe variant we had >99% power to detect a 20% risk reduction in CHD for a 65% genetic reduction in Lp-PLA2 activity (i.e. an effect on Lp-PLA2 activity similar to that achieved by darapladib).